Skip to main content

Table 2 Baseline clinical characteristics according to gender

From: Association between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study

  Male (n = 1348) Female (n = 385) P-value
Age (years) 63.6 ± 11.1 67.5 ± 11.5 <0.01a
Body mass index (kg/m2) 24.5 ± 3.2 24.0 ± 4.3 0.02a
Hypertension 72.6 % 75.1 % 0.36
Diabetes mellitus 41.5 % 31.4 % <0.01a
Dyslipidemia 70.5 % 70.1 % 0.89
Family history of ischemic heart disease 20.0 % 13.2 % <0.01a
Smoking 53.6 % 47.6 % <0.01a
History of coronary revascularization (PCI or CABG) 31.2 % 15.6 % <0.01a
Total cholesterol (mg/dl) 187.1 ± 34.8 202.7 ± 36.8 <0.01a
Triglycerides (mg/dl) 151.8 ± 99.9 130.3 ± 77.6 <0.01a
Low-density lipoprotein cholesterol (mg/dl) 109.8 ± 30.3 115.6 ± 32.2 <0.01a
High-density lipoprotein cholesterol (mg/dl) 48.8 ± 14.3 61.3 ± 19.4 <0.01a
Hemoglobin A1c (%) 6.3 ± 1.1 6.1 ± 1.0 0.02a
Serum creatinine (mg/dl) 0.93 ± 0.29 0.71 ± 0.23 <0.01a
Estimated glomerular filtration rate (ml/min/1.73 m2) 68.8 ± 17.4 68.4 ± 18.7 0.72
EPA (μg/dl) 73.7 ± 43.2 74.4 ± 47.0 0.76
EPA/AA 0.50 ± 0.31 0.46 ± 0.29 0.01a
DHA (μg/dl) 141.8 ± 52.5 149.0 ± 53.2 0.01a
DHA/AA 0.96 ± 0.40 0.92 ± 0.33 0.06
DGLA (μg/dl) 32.7 ± 12.5 35.0 ± 11.5 <0.01a
AA (μg/dl) 154.4 ± 51.3 167.8 ± 41.3 <0.01a
Statins 53.0 % 53.2 % 0.95
Antiplatelet agents 67.9 % 44.7 % <0.01a
Renin angiotensin system inhibitors (ACE-I and ARB) 50.7 % 50.6 % 1.00
Calcium channel blockers 44.4 % 50.1 % 0.04a
Beta blockers 41.7 % 27.8 % <0.01a
Hypoglycemic agents 22.0 % 17.9 % 0.08
  1. Values are mean ± standard deviation, or percentage, aindicates significance, PCI Percutaneous coronary intervention, CABG coronary artery bypass grafting, EPA/AA eicosapentaenoic acid to arachidonic acid ratio, DHA/AA docosahexaenoic acid to arachidonic acid ratio, DGLA dihomo-gamma-linolenic acid, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker